News

The U.S. Food and Drug Administration (FDA) has agreed to review a request to approve Trevyent (treprostinil) as a treatment of pulmonary arterial hypertension (PAH), United Therapeutics announced in a press release. An FDA decision on this updated New Drug Application (NDA) for Trevyent is expected on or before…

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to SoniVie’s Therapeutic Intra-Vascular Ultrasound (TIVUS) System for the treatment of people with pulmonary arterial hypertension (PAH). Similar to breakthrough therapy, the designation of breakthrough device is given to medical equipment…

Swedish men and women who have been diagnosed with idiopathic pulmonary arterial hypertension (IPAH) in recent years have similar survival rates, study says. The study, “Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008–2016,” was published in the journal ERJ Open Research. IPAH, a form of…

Targeting the pro-inflammatory TGF-β signaling pathway in specific cells of the pulmonary arteries — those with high levels of a protein called periostin — shows promise in treating pulmonary arterial hypertension (PAH), a study reports. The study, “Periostin-expressing cell-specific transforming growth factor-β inhibition in pulmonary artery prevents pulmonary arterial…

Online forums have markedly altered how patients, caregivers, and healthcare professionals communicate and connect. Even when miles apart, people can establish supportive relationships, share experiences and information, and sometimes simply vent. Bionews Services, a leading online health, science, and research publication company, has been rolling out…

Rare diseases deeply affect not only the children who experience them, but also their healthy brothers and sisters, as their parents can attest.    Two entries in November’s “Disorder: The Rare Disease Film Festival” will focus on what siblings go through, according to the San Francisco festival’s co-founder,…